In his New Year’s message, issued on Jan. 2, Chmn. Lee Jang-han of Chong Kun Dang Holdings Corp. said, “We have to make this a year of establishing realistic strategies and executing them with the goal of maximizing management efficiency.”
Chong Kun Dang held a ceremony to kick off the 2025 business year at its headquarters in Chungjeong-ro, Seoul, on the same day.
The event was streamed via an online network with Hyo-Jong Research Institute and plant in Cheonan.
Chmn. Lee said, “Resources and capabilities will be concentrated on core businesses and more innovative changes need to be made in the R&D sector.”
“We have to maximize the efficiency based on digital systems, such as AI and secure our own platform technology in not only synthetic drugs but also areas, such as antibody treatment drugs like antibody-drug conjugates (ADC), and cell and gene therapies (CGT),” he said.
Chmn. Lee said, “We’re urgently required to develop innovative new drugs that lead the world through the convergence of various modalities such as targeted protein degraders (TPD), degradable antibody conjugates (DAC), and immune ADCs, and Chong Kun Dang will have to clarify a future roadmap to muster all our executives and staffers’ capabilities to build a global competitiveness.”
“Nexavar” and “Stivarga,” being exclusively distributed in Korea by Chong Kun Dang Pharmaceutical.
Chong Kun Dang Exclusively Distributes Bayer’s ‘Nexavar’ and ‘Stivarga’
Chong Kun Dang Pharmaceutical has struck a deal with Bayer Korea to exclusively distribute and sell the latter’s “Nexavar” (sorafenib tosylate (micronized)) and “Stivarga” (regorafenib) for treating advanced hepatocellular carcinoma (HCC) in Korea.
Under the deal, Chong Kun Dang will be responsible for exclusive distribution, sale and marketing of Nexavar and Stivarga to Korean hospitals and clinics starting in February. Nexavar and Stivarga are used as targeted therapies for HCC.
In 2018, Stivarga became the nation’s first second-line treatment for HCC to be covered by health insurance in Korea, making it a reimbursed second-line treatment option that can be continued alongside the first-line treatment Nexavar.
Since their launches, both treatment drugs have secured clinical evidence through clinical trials and real-world studies.
Chong Kun Dang Pharm CEO Kim Young-joo said, “Chong Kun Dang has recently stepped up its expertise in the anticancer business by setting up a dedicated anticancer body, and we’re expected to ramp up our presence in the Korean anticancer drug market by building up a stronger anticancer portfolio on the back of the exclusive distribution of Nexavar and Stivarga.”
Bayer Korea CEO Lee Jin-ah said, “Based on trust the two companies have accumulated for a long-period time, I’m pleased to supply Bayer’s products together with Chong Kun Dang Pharmaceutical, a company with differentiated competitiveness in the field of anticancer drugs, and the partnership is expected to contribute to improving the quality of life of liver cancer patients in Korea by seamlessly supplying treatment options, such as Nexavar and Stivarga.”
Chong Kun Dang and Bayer Korea joined forces to sell the antibiotics Ciprobay (ciprofloxacin) and Avelox (moxifloxacin) since 2005, and Kerendia (finerenone) for chronic kidney disease with type 2 diabetes since 2024.
The two companies have built a successful partnership as Bayer Korea's cardiovascular drugs Aspirin Protect (acetylsalicylic acid) and Adalat Oros (nifedipine) are also distributed exclusively by Chong Kun Dang.
Hangover treatment drink “Kkaenoni Thank-you Shot.” (Photos: Chong Kun Dang)
Chong Kun Dang Launches ‘Kkaenoni Thank-you Shot’ TV Commercial
Chong Kun Dang has selected actor Koo Kyo-hwan as a model to promote the hangover treatment brand “Kkaenoni” and unveiled a teaser of its TV commercial. The original broadcast will be released later.
The recently released hangover treatment “Kkaenoni Thank-you Shot” contain “Nonitri,” a patented material proved to have an effect of curing hangover by the Ministry of Food and Drug Safety on top of high-density vitamins and milk thistle extracts.
_종근당홀딩스 이장한 회장.jpg)
